Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Keywords: COPD glycopyrronium bromide antimuscarinic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 281
Healthy volunteers: no

Brief summary:
This study assessed the safety/tolerability of 28 days of treatment with NVA237 100 µg and 200 µg once a day, compared to placebo in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD).

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: NVA237 100 µg intervention 2: Placebo intervention 3: NVA237 200 µg
Intervention descriptions: intervention 1: Dry powder inhalation once a day for up to 28 days intervention 2: Placebo to NVA237 dry powder inhalation once a day for up to 28 days intervention 3: Dry powder inhalation once a day for up to 28 days

Protocol document: